Skip to content

”We added focus, simplified the structure, and delivered better financial performance. We will build on that momentum to further grow our businesses and accelerate earnings growth driven by the Operating Companies Fresenius Kabi and Fresenius Helios.”

Michael Sen, CEO Fresenius


Our new corporate structure places a clear focus on our Operating Companies Fresenius Kabi and Fresenius Helios. Both businesses are at the center of our ambitions under #FutureFresenius.

Our Operating Companies Fresenius Kabi and Fresenius Helios are in the focus of our Group’s ambitions under #FutureFresenius. Both businesses have attractive market positions and excellent opportunities for profitable growth. Our Investment Companies – Fresenius Medical Care and Fresenius Vamed – are geared towards financial value management.

At the same time, we started to divest businesses where we were no longer the “best owner”. In 2023, we sold our hospital business in Peru and the fertility service group Eugin, terminated the operations of Curalie and we are streamlining Fresenius Kabi’s production network.

Our Operating Companies at a glance

Both businesses have attractive market positions and excellent opportunities for profitable growth:

Kabi’s Vision 2026 in brief

Broaden Biopharma, expand MedTech, roll-out Nutrition, and build greater resilience in Pharma.

Helios, the largest private health care provider in Europe

At Fresenius Helios, we treat around 26 million patients each year.

Product Highlight Kabi

In 2023, Fresenius Kabi launched the first approved tocilizumab biosimilar in the EU.

Project Highlight Helios

In 2023, Madrid's Quirónsalud University Hospital cut cancer treatment costs by 24% whilst doubling daily treated outpatients.

Our success stories

With our Operating Companies we are uniquely positioned to cater system-critical products and services for leading therapies. We made significant progress over the past year.

Our Operating Company Fresenius Kabi successfully implements its Vision 2026 strategy in line with #FutureFresenius. The company specializes in products for the therapy and care of critically and chronically ill patients. The portfolio includes biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs (generic IV drugs), and IV fluids.

In 2023, Fresenius Kabi…

  • launched Tyenne, the first approved tocilizumab biosimilar in the EU: Showcasing our commitment to patient care, strengthening our growth profile, expanding our biopharma portfolio, and demonstrating our ability to develop state-of-the-art medicines.
  • signed a multi-year supply and service agreement with the Mayo Clinic to purchase 10,000 Ivenix large-volume infusion pumps for its hospitals and clinics; this is the largest contract Fresenius Kabi has signed for Ivenix pumps to date.
  • was named Supplier Partner of the Year by Vizient, the largest U.S. provider of healthcare performance improvement services; this recognition reflects Fresenius Kabi’s commitment to collaboration and innovation to enhance quality of care and patient safety.

Our Operating Company Fresenius Helios is Europe’s leading private healthcare provider with more than 125,000 employees. Helios Germany and Helios Spain (operates as Quirónsalud) are the largest private hospital operators in their respective home markets. Every year about 26 million patients choose Fresenius Helios for medical treatment.

In 2023, Fresenius Helios…

  • piloted the use of AI building automation, employing a digital twin for the ENDO clinic in Hamburg to forecast and optimize energy usage, resulting in a 20% potential reduction in energy consumption and CO2 emissions, opening a new chapter in the optimization of our hospital building efficiency.
  • finalized the so-called “HOPE” project: Quirónsalud’s University Hospital in Madrid developed and launched an initiative, which combines technical innovation and an integrated practice unit model, resulting in a 24% decrease in cancer treatment costs, a doubling of daily treated outpatients, and significant reductions in hospital admissions and overall process time.

Discover more about our Fresenius Financial Framework in the next story “Performance”


Fresenius SE & Co. KGaA
Investor Relations
+49 (0) 6172 608-2485

Related Links


Share Price

Data is delayed by 15 minutes.

Share Price Information